| Literature DB >> 35116799 |
Ruowen Xiao1, Lu Shi2, Te Yang3, Meiyin Zhang1, Huiyun Wang1, Shijuan Mai1.
Abstract
BACKGROUND: Nasopharyngeal carcinoma (NPC) is a highly aggressive neoplasm mainly distributed in the eastern and southeastern parts of Asia. NPC has a poor prognosis among head and neck cancers, and molecular-targeted therapies showed limited clinical efficacy.Entities:
Keywords: Nasopharyngeal carcinoma (NPC); RRAS; functional enrichment analysis; hub gene; pathway crosstalk
Year: 2019 PMID: 35116799 PMCID: PMC8798477 DOI: 10.21037/tcr.2019.04.04
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
Figure 1Significantly enriched GO terms. GO, Gene Ontology.
Gene ontology biological process terms enriched in NPC-related genes
| Gene set | Description | No. of genes | P value | FDR |
|---|---|---|---|---|
| GO:0001667 | Ameboidal-type cell migration | 46 | 0 | 0 |
| GO:0002521 | Leukocyte differentiation | 53 | 0 | 0 |
| GO:0006979 | Response to oxidative stress | 53 | 0 | 0 |
| GO:0007050 | Cell cycle arrest | 38 | 0 | 0 |
| GO:0007159 | Leukocyte cell-cell adhesion | 64 | 0 | 0 |
| GO:0007346 | Regulation of mitotic cell cycle | 67 | 0 | 0 |
| GO:0007568 | Aging | 52 | 0 | 0 |
| GO:0009314 | Response to radiation | 60 | 0 | 0 |
| GO:0009612 | Response to mechanical stimulus | 35 | 0 | 0 |
| GO:0009617 | Response to bacterium | 61 | 0 | 0 |
| GO:0010035 | Response to inorganic substance | 57 | 0 | 0 |
| GO:0022407 | Regulation of cell-cell adhesion | 53 | 0 | 0 |
| GO:0033002 | Muscle cell proliferation | 39 | 0 | 0 |
| GO:0033674 | Positive regulation of kinase activity | 57 | 0 | 0 |
| GO:0040017 | Positive regulation of locomotion | 60 | 0 | 0 |
| GO:0042493 | Response to drug | 58 | 0 | 0 |
| GO:0044770 | Cell cycle phase transition | 62 | 0 | 0 |
| GO:0045785 | Positive regulation of cell adhesion | 57 | 0 | 0 |
| GO:0045787 | Positive regulation of cell cycle | 48 | 0 | 0 |
| GO:0048514 | Blood vessel morphogenesis | 66 | 0 | 0 |
| GO:0048545 | Response to steroid hormone | 48 | 0 | 0 |
| GO:0048732 | Gland development | 59 | 0 | 0 |
| GO:0050673 | Epithelial cell proliferation | 56 | 0 | 0 |
| GO:0050900 | Leukocyte migration | 53 | 0 | 0 |
| GO:0051052 | Regulation of DNA metabolic process | 48 | 0 | 0 |
| GO:0051090 | Regulation of sequence-specific DNA binding transcription factor activity | 48 | 0 | 0 |
| GO:0051098 | Regulation of binding | 45 | 0 | 0 |
| GO:0051272 | Positive regulation of cellular component movement | 58 | 0 | 0 |
| GO:0070482 | Response to oxygen levels | 55 | 0 | 0 |
| GO:0070997 | Neuron death | 49 | 0 | 0 |
| GO:0071216 | Cellular response to biotic stimulus | 38 | 0 | 0 |
| GO:0071417 | Cellular response to organonitrogen compound | 55 | 0 | 0 |
| GO:0071900 | Regulation of protein serine/threonine kinase activity | 57 | 0 | 0 |
| GO:0090130 | Tissue migration | 41 | 0 | 0 |
| GO:0097191 | Extrinsic apoptotic signaling pathway | 42 | 0 | 0 |
| GO:0097193 | Intrinsic apoptotic signaling pathway | 41 | 0 | 0 |
| GO:2001233 | Regulation of apoptotic signaling pathway | 55 | 0 | 0 |
| GO:0031589 | Cell-substrate adhesion | 42 | 1.11E−16 | 2.23E−15 |
| GO:0007369 | Gastrulation | 32 | 2.22E−16 | 4.34E−15 |
| GO:0048144 | Fibroblast proliferation | 23 | 4.44E−16 | 8.46E−15 |
| GO:0018212 | Peptidyl-tyrosine modification | 45 | 6.66E−16 | 1.24E−14 |
| GO:0071559 | Response to transforming growth factor beta | 34 | 1.78E−15 | 3.22E−14 |
| GO:0001101 | Response to acid chemical | 41 | 2.44E−15 | 4.23E−14 |
| GO:0071214 | Cellular response to abiotic stimulus | 39 | 2.44E−15 | 4.23E−14 |
| GO:0002764 | Immune response-regulating signaling pathway | 50 | 3.33E−15 | 5.64E−14 |
| GO:0031349 | Positive regulation of defense response | 46 | 4.22E−15 | 6.99E−14 |
| GO:1901652 | Response to peptide | 48 | 7.55E−15 | 1.22E−13 |
| GO:0072331 | Signal transduction by p53 class mediator | 36 | 1.02E−14 | 1.62E−13 |
| GO:0001819 | Positive regulation of cytokine production | 44 | 1.19E−14 | 1.85E−13 |
Figure 2Significantly enriched KEGG pathways of NPCgset. KEGG, Kyoto Encyclopedia of Genes and Genomes.
Figure 3Pathway crosstalk among NPCgset-enriched pathways. Nodes represent pathways, and edges represent crosstalk between pathways. Edge-width corresponds to the score of the specific pathway pair; larger edge-width indicates a higher score.
Figure 4Protein-protein interaction analysis. (A) Protein-protein interaction network constructed with the eight duplicate genes and hub gene identification, and darker color and larger size indicate a higher degree; (B) protein-protein interaction network of proteins associated with PIK3CA. Darker color and larger size indicate a higher degree.
Connectivity degree of genes
| Gene symbol | Degree |
|---|---|
|
| 3 |
|
| 6 |
|
| 5 |
|
| 5 |
|
| 5 |
|
| 6 |
|
| 7 |
|
| 7 |
Figure S1Expression level of IRS2 mRNA in NPC cell lines and tissues. (A) Expression level of IRS2 mRNA in nasopharyngeal cell lines and immortalized epithelial cell line NP69; (B) expression level of IRS2 mRNA in 16 NPC tissues and 15 noncancerous nasopharyngeal tissues. NPC, nasopharyngeal carcinoma.
Figure 5RRAS is down-regulated in NPC and correlates with poor prognosis. (A) Expression level of RRAS mRNA in nasopharyngeal cell lines and immortalized epithelial cell line NP69; (B) the expression level of RRAS mRNA in 16 NPC tissues and 15 noncancerous nasopharyngeal tissues; (C) the expression level of RRAS protein in NPC cell lines and the immortalized epithelial cell line NP69 was analyzed by western blot; (D) representative immunohistochemical staining of RRAS protein in NPC specimens; (E) Kaplan-Meier survival analysis indicated that patients with high expression of RRAS had a longer overall survival (OS), but had no significant correlation with progression-free survival (PFS). P<0.05 was regarded as statistically significant. **, P<0.01; ***, P<0.001. NPC, nasopharyngeal carcinoma.
Association of RRAS expression with clinicopathological features of NPC
| Variable | No. | RRAS expression | P value (χ2-test) | |
|---|---|---|---|---|
| Low (n=32) | High (n=33) | |||
| Gender | 0.341 | |||
| Female | 15 | 9 (60.0) | 6 (40.0) | |
| Male | 50 | 23 (46.0) | 27 (54.0) | |
| Age | 0.108 | |||
| <45 | 30 | 18 (60.0) | 12 (40.0) | |
| ≥45 | 35 | 14 (40.0) | 21 (60.0) | |
| EA/IgA | 0.388 | |||
| <1:20 | 31 | 17 (54.8) | 14 (45.2) | |
| ≥1:20 | 34 | 15 (44.1) | 19 (55.9) | |
| VCA/IgA | 0.953 | |||
| <1:160 | 12 | 6 (50.0) | 6 (50.0) | |
| ≥1:160 | 53 | 26 (49.1) | 27 (50.9) | |
| Clinical staging | 0.019* | |||
| I–III | 34 | 12 (35.3) | 22 (64.7) | |
| VI | 31 | 20 (64.5) | 11 (35.5) | |
| Distant metastasis | 0.082 | |||
| No | 47 | 20 (42.6) | 27 (57.4) | |
| Yes | 18 | 12 (66.7) | 6 (33.3) | |
*P<0.05. NPC, nasopharyngeal carcinoma.
Univariate and multivariate analyses on clinicopathologic features of NPC patients
| Factors | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Age: <45 | 0.570 (0.240–1.353) | 0.203 | – | – | |
| Gender: female | 0.976 (0.361–2.641) | 0.962 | – | – | |
| EA/IgA: <1:20 | 0.928 (0.407–2.119) | 0.86 | – | – | |
| VCA/IgA: <1:160 | 0.899 (0.304–2.659) | 0.0847 | – | – | |
| Clinical staging: I–III | 0.307 (0.129–0.727) | 0.007** | – | – | |
| Distant metastasis: no | 0.126 (0.051–0.309) | <0.001*** | 0.146 (0.059–0.364) | <0.001*** | |
| RRAS expression: low | 3.045 (1.282–7.230) | 0.012* | 2.244 (0.925–5.441) | 0.074# | |
#, P<0.1; *, P<0.05; **, P<0.01; ***, P<0.001. NPC, nasopharyngeal carcinoma.
Figure 6RRAS knockdown promotes cell proliferation, invasion, and EMT. (A) CCK8 assays showed that RRAS knockdown significantly promotes the proliferation of HK1 and 5-8F cells compared with the controls; (B) colony formation assays showed that RRAS knockdown significantly promotes the growth of HK1 and 5-8F cells compared with the controls; (C) the invasion ability of HK1 and 5-8F cells were significantly enhanced after RRAS depletion (sclar bar =200 µm); (D) the knockdown efficiency of RRAS in HK1 and 5-8F cells were confirmed by Western blot, and knockdown of RRAS decreased the expression of E-cadherin and increased the expression of N-cadherin, vimentin. P<0.05 was regarded as statistically significant. *, P<0.05; **, P<0.01; ***, P<0.001. EMT, epithelial-mesenchymal transformation.